Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Bharat Kumar Reddy Sanapalli, Elango Kannan, Shivaramakrishnan Balasubramanian, Jawahar Natarajan, Uday Krishna Baruah & Veera Venkata Satyanarayana Reddy Karri. (2018) Pluronic lecithin organogel of 5-aminosalicylic acid for wound healing. Drug Development and Industrial Pharmacy 44:10, pages 1650-1658.
Read now
Read now
Kavinderjit Nanda & Alan C Moss. (2012) Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. Clinical Pharmacology: Advances and Applications 4, pages 41-50.
Read now
Read now
Maggie Ham & Alan C Moss. (2012) Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Review of Clinical Pharmacology 5:2, pages 113-123.
Read now
Read now
Garrett Lawlor, Awais Ahmed & Alan C Moss. (2010) Once-daily mesalamine granules for ulcerative colitis. Expert Review of Clinical Immunology 6:4, pages 521-526.
Read now
Read now
Laura Noddin Rosenberg & Mark A Peppercorn. (2010) Efficacy and safety of drugs for ulcerative colitis. Expert Opinion on Drug Safety 9:4, pages 573-592.
Read now
Read now
Mary Y Hu & Mark A Peppercorn. (2008) MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis. Expert Opinion on Pharmacotherapy 9:6, pages 1049-1058.
Read now
Read now
Articles from other publishers (30)
Joanna Słoka, Marcel Madej & Barbara Strzalka-Mrozik. (2023) Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer. Molecules 28:13, pages 5081.
Crossref
Crossref
Wenlong Fu, Lei Xie, Jicheng Yu, Yanjun He, Jie Zeng, Jian Liu, Kang Liang, Pu Chen, Lei Jiang, Zhen Gu & Biao Kong. (2023)
In Situ
Interfacial Super-Assembly of Nanobiohybrids through Plant for Food-Grade Oral Medicine
. ACS Applied Materials & Interfaces 15:5, pages 7282-7293.
Crossref
Crossref
Shraddha Saha, Jinal Naik, Natarajan Amaresan & Meonis Pithawala. (2022) In silico analysis of Typha domingensis Pers. phytocompounds against wound healing biomarkers and ascertaining through in vitro cell migration assay. 3 Biotech 12:8.
Crossref
Crossref
Sasha R. Fehily, Aysha H. Al‐Ani, Jonathan Abdelmalak, Clarissa Rentch, Eva Zhang, Justin T. Denholm, Douglas Johnson, Siew C. Ng, Vishal Sharma, David T. Rubin, Peter R. Gibson & Britt Christensen. (2022) Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management. Alimentary Pharmacology & Therapeutics 56:1, pages 6-27.
Crossref
Crossref
Simran Shergill. (2021) Mesalazine-induced myopericarditis: a case report. European Heart Journal - Case Reports 5:2.
Crossref
Crossref
Richa Chibbar & Alan C. Moss. (2020) Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterology Clinics of North America 49:4, pages 689-704.
Crossref
Crossref
Sasha R. Fehily, Felicity C. Martin & Michael A. Kamm. (2019) Simple water‐based tacrolimus enemas for refractory proctitis. JGH Open 4:4, pages 561-564.
Crossref
Crossref
Shiva T. Radhakrishnan, Aruchuna Mohanaruban & Sami Hoque. (2018) Mesalazine-induced myocarditis: a case report. Journal of Medical Case Reports 12:1.
Crossref
Crossref
Hilal Ahmad & Vijay L. Kumar. (2018) Pharmacotherapy of ulcerative colitis – current status and emerging trends. Journal of Basic and Clinical Physiology and Pharmacology 29:6, pages 581-592.
Crossref
Crossref
Sasha R. Fehily, Nik M. Partsanis & Britt Christensen. (2018) Cough in the Immunosuppressed Patient. Gastroenterology.
Crossref
Crossref
Frank Karkossa & Sandra Klein. (2018) A Biopredictive In Vitro Comparison of Oral Locally Acting Mesalazine Formulations by a Novel Dissolution Model for Assessing Intraluminal Drug Release in Individual Subjects. Journal of Pharmaceutical Sciences 107:6, pages 1680-1689.
Crossref
Crossref
Paisit Paueksakon & Agnes B Fogo. (2017) Drug-induced nephropathies. Histopathology 70:1, pages 94-108.
Crossref
Crossref
Gary R. Lichtenstein, Glenn L. Gordon, Salam Zakko, Uma Murthy, Shahriar Sedghi, Ron Pruitt, Andrew C. Barrett, Enoch Bortey, Craig Paterson & William P. Forbes. (2015) Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Digestive Diseases and Sciences 61:1, pages 221-229.
Crossref
Crossref
Bei Ye. (2015) Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?. World Journal of Gastrointestinal Pharmacology and Therapeutics 6:4, pages 137.
Crossref
Crossref
Maricelma da Silva Soares de Souza, Sandra Maria Barbalho, Ricardo de Alvares Goulart & Antonely de Cássio Alves de Carvalho. (2015) The Current and Future Role of Drugs and Probiotics in the Management of Inflammatory Bowel Disease. Journal of Biosciences and Medicines 03:08, pages 76-85.
Crossref
Crossref
Anita Annaházi & Tamás Molnár. (2015) Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterology Research and Practice 2015, pages 1-18.
Crossref
Crossref
Marine Auffret, Johana Béné, Marc Lambert & Sophie Gautier. (2014) Pneumopathie interstitielle diffuse sous mésalazine : un effet indésirable sous diagnostiqué ?. Therapies 69:6, pages 531-532.
Crossref
Crossref
Hannah L. Miller & Francis A. Farraye. 2014. Pocket Guide to Gastrointestinal Drugs. Pocket Guide to Gastrointestinal Drugs
82
99
.
Kousaku Kawashima, Shunji Ishihara, Takafumi Yuki, Koji Onishi, Yoshinori Kushiyama, Hirofumi Fujishiro, Youichi Miyaoka, Mika Yuki, Yoshinori Komazawa, Takashi Tanimura, Hiroki Sonoyama, Yasumasa Tada, Ryusaku Kusunoki, Akihiko Oka, Nobuhiko Fukuba, Naoki Oshima, Ichiro Moriyama & Yoshikazu Kinoshita. (2014) Therapeutic Efficacy of pH-Dependent Release Formulation of Mesalazine on Active Ulcerative Colitis Resistant to Time-Dependent Release Formulation: Analysis of Fecal Calprotectin Concentration. BioMed Research International 2014, pages 1-6.
Crossref
Crossref
Per Karlén. (2013) Mesalazine-induced renal calculi. American Journal of Case Reports 14, pages 551-553.
Crossref
Crossref
Pascal Frei, Luc Biedermann, Christine N. Manser, Maike Wilk, Michael Manz, Stephan R. Vavricka & Gerhard Rogler. (2012) Topical Therapies in Inflammatory Bowel Disease. Digestion 86:s1, pages 36-44.
Crossref
Crossref
Volker Gross, Ivan Bunganic, Elena A. Belousova, Tatyana L. Mikhailova, Limas Kupcinskas, Gediminas Kiudelis, Zsolt Tulassay, Libor Gabalec, Andrey E. Dorofeyev, Jelena Derova, Karin Dilger, Roland Greinwald & Ralph Mueller. (2011) 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial. Journal of Crohn's and Colitis 5:2, pages 129-138.
Crossref
Crossref
G. R. Lichtenstein, G. L. Gordon, S. Zakko, U. Murthy, S. Sedghi, R. Pruitt, K. Merchant, A. Shaw, E. Bortey & W. P. Forbes. (2010) Clinical trial: once‐daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6‐month placebo‐controlled trial. Alimentary Pharmacology & Therapeutics 32:8, pages 990-999.
Crossref
Crossref
Mark A. Perazella & Glen S. Markowitz. (2010) Drug-induced acute interstitial nephritis. Nature Reviews Nephrology 6:8, pages 461-470.
Crossref
Crossref
Bruno Sposato, Maria Pia Allegri, Maria Piera Riccardi, Silvia Chigiotti, Cesira Nencioni, Barbara Ricciardi, Tiziana Carli, Alberto Cresti, Maria Grazia Perari, Maria Giovanna Migliorini & Mario Toti. (2012) Mesalazine-Induced Multi-Organ Hypersensitivity. Clinical Drug Investigation 30:6, pages 413-417.
Crossref
Crossref
Mirna Djuric, Djordje Povazan, Svetozar Secen & Jelena Jovic. (2010) Differential diagnosis problem of pulmonary changes in ulcerative colitis. Vojnosanitetski pregled 67:6, pages 511-514.
Crossref
Crossref
Pim J. Koelink, Lukas J.A.C. Hawinkels, Eliza Wiercinska, Cornelis F.M. Sier, Peter ten Dijke, Cornelis B.H.W. Lamers, Daan W. Hommes & Hein W. Verspaget. (2010) 5-Aminosalicylic acid inhibits TGF-β1 signalling in colorectal cancer cells. Cancer Letters 287:1, pages 82-90.
Crossref
Crossref
Yusuf Usta, Hasan Ozen, Figen Gurakan, Nuray Uslu, Inci Nur Saltik-Temizel, Hulya Demir & Aysel Yuce. (2009) Hypereosinophilia Due to Mesalazine Treatment. Journal of Clinical Gastroenterology 43:4, pages 382.
Crossref
Crossref
M.R. Atienza Amores, I. Martín-Garrido, R. García-Contreras & J.M. Varela Aguilar. (2009) Alopecia como reacción adversa de la mesalazina. Revista Clínica Española 209:3, pages 153-154.
Crossref
Crossref
Nielsen Q Fernandez-Becker & Alan C Moss. (2008) Improving Delivery of Aminosalicylates in Ulcerative Colitis. Drugs 68:8, pages 1089-1103.
Crossref
Crossref